Fasudil

Fasudil
Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	C04AX32 (WHO) ;
Pharmacokinetic data
Metabolites	Hydroxyfasudil
Elimination half-life	0.76 hours. Active metabolite (hydroxyfasudil) 4.66 hours.
Identifiers
	IUPAC name 5-(1,4-Diazepane-1-sulfonyl)isoquinoline;
CAS Number	103745-39-7 ;
PubChem CID	3547;
IUPHAR/BPS	5181;
DrugBank	DB08162 ;
ChemSpider	3426 ;
UNII	Q0CH43PGXS;
KEGG	D07941 ;
ChEBI	CHEBI:43871;
ChEMBL	ChEMBL38380 ;
PDB ligand	M77 (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID4048569 ;
ECHA InfoCard	100.250.347
Chemical and physical data
Formula	C14H17N3O2S
Molar mass	291.37 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CNCCN(C1)S(=O)(=O)C2=CC=CC3=C2C=CN=C3;
	InChI InChI=1S/C14H17N3O2S/c18-20(19,17-9-2-6-15-8-10-17)14-4-1-3-12-11-16-7-5-13(12)14/h1,3-5,7,11,15H,2,6,8-10H2 ; Key:NGOGFTYYXHNFQH-UHFFFAOYSA-N ;
	(what is this?) (verify)

Fasudil (INN) is a potent Rho-kinase inhibitor and vasodilator. Since it was discovered, it has been used for the treatment of cerebral vasospasm, which is often due to subarachnoid hemorrhage, as well as to improve the cognitive decline seen in stroke patients. It has been found to be effective for the treatment of pulmonary hypertension. It has been demonstrated that fasudil could improve memory in normal mice, identifying the drug as a possible treatment for age-related or neurodegenerative memory loss.

It has been approved for use in Japan and China since 1995, but has not been approved by the United States Food and Drug Administration or by the European Medicines Agency. Woolsey Pharmaceuticals is developing BRAVYL (oral fasudil) for various neurodegenerative diseases.